Has Tecentriq earned a role in treatment of triple-negative breast cancer? Here is what experts say

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Obviously, the field of immune-oncology has been one of the great success stories in our field over the last five years, based on our molecular understanding of the mechanisms of immune tolerance (or checkpoints) and how to disrupt that. Not only has ASCO declared Checkpoint Inhibition (as well as cellular-based immunotherapy) the “Advance of the Year,” the Nobel Committee awarded this year’s Prize to Drs. Allison and Honjo for their fabulous observations that led to these great breakthroughs.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Daniel Hayes
Stuart B. Padnos Professor of Breast Cancer Research, University of Michigan Rogel Cancer Center
Chief scientific and medical officer, American Cancer Society
Former member of the FDA Oncologic Drugs Advisory Committee
Ballvé Lantero Professor of Oncology, IU School of Medicine, Associate director of clinical research, Indiana University Melvin and Bren Simon Cancer Center
In This Issue

YOU MAY BE INTERESTED IN

President Joe Biden’s proposed Advanced Research Projects Agency-Health would be a welcome partner to NCI—particularly in conducting large, collaborative clinical investigations, NCI Director Ned Sharpless said.“I think having ARPA-H as part of the NIH is good for the NCI,” Sharpless said April 11 in his remarks at the annual meeting of the American Association for Cancer Research. “How this would fit with the ongoing efforts in cancer at the NCI is still something to work out.”
Daniel Hayes
Stuart B. Padnos Professor of Breast Cancer Research, University of Michigan Rogel Cancer Center
Chief scientific and medical officer, American Cancer Society
Former member of the FDA Oncologic Drugs Advisory Committee
Ballvé Lantero Professor of Oncology, IU School of Medicine, Associate director of clinical research, Indiana University Melvin and Bren Simon Cancer Center

Login